By Jody Godoy PHILADELPHIA, March 17 (Reuters) - The U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical industry with a number of blockbuster drugs ‌near the end of their patents, the FTC's head of antitrust enforcement said on ‌Tuesday, as the agency looks to protect consumers from unfair prices. Monitoring the shift in the market brought about by patent expirations ​is part of the FTC's "laser focus" on healthcare, Dan Guarnera, director of the FTC's b ...